Simvastatin is a specific inhibitor of HMG-CoA reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonate.

The use of HMG box-binding molecules and molecules having sequence homology with HMG box for the preparation of therapeutic agents for the treatment of vascular diseases is described.

The dosage form provides improved chemical stability of the HMG-CoA reductase inhibitor.

However, hGH is only bioavailable in the injectable form.

The present invention is in relation to a process for preparation of HMG-CoA reductase inhibitor.

Some women do suffer from side effects of hMG’s.

In addition, HMG increases luteinizing hormone production.

The compound of the present invention has an inhibitive effect on HMG-CoA reductase.

These are called human menopausal gonadotrophins (hMG).

These medications are known as Menopur and hMG-lepori.

The products obtained are suitable as HMG-CoA reductase inhibitors or intermediates thereof.

The invention relates to a method for producing statins known as HMG-CoA reductase inhibitors.

The lipid lowering agent is selected from HMG Co-enzyme-A reductase inhibitor.

The HMG-CoA reductase inhibitor is preferably delivered to the site by a carrier.

In a preferred embodiment, the HMG-CoA reductase inhibitor is lovastatin.